XBiotech Inc. (XBIT) Reaches $10.35 After 6.00% Up Move; Viper Energy Partners Lpunit (VNOM) Shorts Decreased By 25.39%

XBiotech Inc. (NASDAQ:XBIT) Logo

The stock of XBiotech Inc. (NASDAQ:XBIT) is a huge mover today! The stock increased 5.18% or $0.51 during the last trading session, reaching $10.35. About 120,105 shares traded. XBiotech Inc. (NASDAQ:XBIT) has risen 90.53% since March 19, 2018 and is uptrending. It has outperformed by 86.16% the S&P500. Some Historical XBIT News: 16/04/2018 – XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 02/04/2018 – XBIOTECH INC – HAS OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG; 16/04/2018 – XBIOTECH INC – CONDUCTING FINAL PREPARATIONS FOR STUDY LAUNCH INCLUDING FIRST CLINICAL SITE INITIATION SCHEDULED LATER THIS MONTH; 02/04/2018 XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer; 16/04/2018 – XBIOTECH INC – CO WOULD EVALUATE A NEW SUBCUTANEOUS FORMULATION OF CO’S TRUE HUMAN MONOCLONAL ANTIBODY, MABP1, IN TWO SEPARATE PHASE 2 STUDIES; 16/04/2018 – XBIOTECH INC – UPCOMING PHASE 2 CLINICAL STUDIES IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS (AD) AND HIDRADENITIS SUPPURATIVA (HS); 02/04/2018 – XBIOTECH IN-LICENSES ANTI-NY-ESO-1 ANTIBODY FROM CT ATLANTIC; 02/04/2018 – XBIOTECH INC – OBTAINED AN EXCLUSIVE, WORLDWIDE LICENSE FROM CT ATLANTIC AG, A SWISS BIOTECHNOLOGY COMPANY; 16/04/2018 – Press Release: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology; 22/05/2018 – XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic DermatitisThe move comes after 8 months positive chart setup for the $370.74 million company. It was reported on Mar, 19 by Barchart.com. We have $10.97 PT which if reached, will make NASDAQ:XBIT worth $22.24M more.

Viper Energy Partners Lpunit (NASDAQ:VNOM) had a decrease of 25.39% in short interest. VNOM’s SI was 1.66M shares in March as released by FINRA. Its down 25.39% from 2.23M shares previously. With 745,300 avg volume, 2 days are for Viper Energy Partners Lpunit (NASDAQ:VNOM)’s short sellers to cover VNOM’s short positions. The SI to Viper Energy Partners Lpunit’s float is 3.29%. The stock decreased 1.09% or $0.37 during the last trading session, reaching $33.47. About 158,961 shares traded. Viper Energy Partners LP (NASDAQ:VNOM) has risen 43.42% since March 19, 2018 and is uptrending. It has outperformed by 39.05% the S&P500. Some Historical VNOM News: 29/03/2018 – VIPER ENERGY PARTNERS – MINERALS BUSINESS TO CONTINUE TO BE TAXED AS PARTNERSHIP FOR FEDERAL, STATE INCOME TAX PURPOSES; 03/05/2018 – VIPER ENERGY PARTNERS LP VNOM.O : NORTHLAND CAPITAL RAISES TARGET PRICE TO $38 FROM $29; 24/04/2018 – US OIL & GAS EXPLORATION & PRODUCTION : CREDIT SUISSE SAYS EQT CORP AND RANGE RESOURCES CORP ARE TOP GAS PICKS; 03/04/2018 – Viper Networks Engages ChainBytes for Weather Capture Development on Smart LED Poles; 09/05/2018 – Viper Energy Partners LP, A Subsidiary Of Diamondback Energy, Inc., Announces Effective Date Of Tax Status Change From Pass-Through Partnership To A Taxable Entity; 23/05/2018 – Viper Equity Partners of Palm Beach Brings Private Equity Firms and Healthcare Together; 21/03/2018 – Former Viper Plant to Become New Home of FCA US Car Collection; Company Launches Viper Memorabilia Auction to Benefit United Way; 17/05/2018 – Dodge and Barrett-Jackson Bring Historical Charity Sale to 2018 Northeast Auction with Last 2018 Dodge Challenger SRT Demon and 2017 Dodge Viper; 29/03/2018 – VIPER ENERGY PARTNERS LP – BELIEVES THIS ELECTION WILL ALLOW CO TO SIGNIFICANTLY EXPAND INVESTOR BASE, BOTH IN U.S. & INTERNATIONALLY; 24/04/2018 – US OIL & GAS EXPLORATION & PRODUCTION : CREDIT SUISSE SAYS MARATHON OIL, ANADARKO PETROLEUM, NOBLE ENERGY, VIPER ENERGY, EXTRACTION OIL & GAS AMONG TOP E&P PICKS

More notable recent Viper Energy Partners LP (NASDAQ:VNOM) news were published by: Nasdaq.com which released: “VNOM Makes Notable Cross Below Critical Moving Average – Nasdaq” on February 27, 2019, also Nasdaq.com with their article: “Viper Energy Partners LP, a Subsidiary of Diamondback Energy, Inc., Prices Upsized Public Offering of Common Units – Nasdaq” published on February 26, 2019, Nasdaq.com published: “Diamondback (FANG) Q4 Earnings Miss as Crude Prices Fall – Nasdaq” on February 20, 2019. More interesting news about Viper Energy Partners LP (NASDAQ:VNOM) were released by: Seekingalpha.com and their article: “Viper Energy Q4 2018 Earnings Preview – Seeking Alpha” published on February 04, 2019 as well as Seekingalpha.com‘s news article titled: “Viper Energy declares $0.51 dividend – Seeking Alpha” with publication date: February 05, 2019.

Among 6 analysts covering Viper Energy Partners (NASDAQ:VNOM), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Viper Energy Partners had 7 analyst reports since September 28, 2018 according to SRatingsIntel. Raymond James maintained Viper Energy Partners LP (NASDAQ:VNOM) rating on Friday, March 1. Raymond James has “Buy” rating and $50 target. The stock has “Buy” rating by Imperial Capital on Friday, March 8. The firm has “Outperform” rating by Credit Suisse given on Tuesday, October 30. PiperJaffray reinitiated Viper Energy Partners LP (NASDAQ:VNOM) on Friday, September 28 with “Overweight” rating. Citigroup maintained Viper Energy Partners LP (NASDAQ:VNOM) on Monday, December 17 with “Buy” rating.

Viper Energy Partners LP owns, acquires, and exploits oil and natural gas properties in North America. The company has market cap of $4.52 billion. The firm holds mineral interests covering an area of approximately 30,442 net acres in the Permian Basin, West Texas. It has a 16.65 P/E ratio. As of December 31, 2015, its estimated proved oil and natural gas reserves consisted of 31,435 thousand barrels of crude oil equivalent.

More important recent XBiotech Inc. (NASDAQ:XBIT) news were published by: Seekingalpha.com which released: “XBiotech up 13% on positive bermekimab data – Seeking Alpha” on March 01, 2019, also Seekingalpha.com published article titled: “XBiotech up 4% premarket on positive bermekimab data – Seeking Alpha”, Globenewswire.com published: “Breakthrough Results from Phase 2 Clinical Trial of Bermekimab in the Treatment of Atopic Dermatitis (AD) to be Presented on March 2, 2019 at American Academy of Dermatology Annual Meeting – GlobeNewswire” on March 01, 2019. More interesting news about XBiotech Inc. (NASDAQ:XBIT) was released by: Seekingalpha.com and their article: “Key events next week – healthcare – Seeking Alpha” with publication date: February 22, 2019.

Viper Energy Partners LP (NASDAQ:VNOM) Ratings Chart

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *